News & Media

  Princeton, N.J. and Deerfield, Ill. – December 15, 2014   – Otsuka America Pharmaceutical, Inc. (OAPI) and Lundbeck today announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for a proposed new injection site—the deltoid muscle of the arm—for Abilify Maintena® (aripiprazole) for extended-release injectable

The head-to-head QUALIFY study compared the effectiveness of aripiprazole once-monthly to paliperidone palmitate once-monthly in adult patients with schizophreniaPatients treated with aripiprazole once-monthly demonstrated a statistically significant improvement on the primary endpoint, quality-of-life measures, compared to those treated with paliperidone palmitateDiscontinuations due to

Dual-chamber syringe offers healthcare providers more flexibility during patient office visitsFirst of several anticipated product enhancements to Abilify Maintena  Princeton, N.J. and Deerfield, Ill. – September 29, 2014 – Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) has approved a

In the clinical program, brexpiprazole demonstrated improvement in symptoms in both schizophrenia and as adjunctive therapy in major depressive disorder (MDD)July 2015 is the anticipated completion timing of the FDA’s review (based on PDUFA timeline)Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) believed to possess a balanced combination of binding affinity and functional